Bradykinin antagonists: new opportunities.
The pro-inflammatory, pain producing, and cardiovascular effects of bradykinin B2 receptor activation are well characterized. Bradykinin B1 receptors also produce inflammation and pain. Therefore, antagonists are expected to be anti-inflammatory/analgesic drugs. Other exploitable clinical opportunities may exist. The newly discovered non-peptide B2 receptor antagonists and the equivalent B1 receptor pharmacological agents, which are in the pipeline, are suitable preclinical tools to properly evaluate potential utilities.
Bock
M G
MG
Merck Research Laboratories, West Point, PA 19486, USA. mark_bock@merck.com
Longmore
J
J
D001920:Bradykinin / Q000037:antagonists & inhibitors*; D065168:Bradykinin Receptor Antagonists; D004355:Drug Stability; D005544:Forecasting; D006801:Humans; D015394:Molecular Structure; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*
D065168:Bradykinin Receptor Antagonists; D009842:Oligopeptides; D001920:Bradykinin